U.S. Supreme Court slaps big pharma for paying generic makers to delay lower cost medications

Ruled 5-3 that agreements between the makers of name-brand and generic drugs to delay the generics' availability can be illegal, an outcome cheered by consumer groups.
CLICK TO VIEW THE SOURCE MATERIAL